Eccogene

Clinical stage biopharmaceutical company developing best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions.

Health and bio

Latest funding

$25.2M Series B+ · June 11, 2023

Source: startupintros.com

Funding history ↓

Website: eccogene.com.

LinkedIn: eccogene.

Category: Health and bio.

Stage: Series B+.

Last round: Jun 11, 2023 · 1,250 days ago.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredNov 29, 2017 (8 years old)

Funding rounds

June 11, 2023
Series B+ · $25.2M
Source: startupintros.com
November 29, 2017
Website created

Founders and team

JZ
Jingye Zhou Co-founder & CEO

source: eccogene.com
JX
Jianfeng Xu Co-founder & CSO

source: eccogene.com

Companies like Eccogene

AAltay Therapeutics
SSudo Bio$37M Series A · Sep 2022
NNoema PharmaSeries B+ · Nov 2025
DDiadem Biotherapeutics
RRevier Therapeutics$6.95M Seed · Aug 2026
MMwyngil TherapeuticsSeed · Jun 2026

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/eccogene (get a free API key).